Uncategorized

AB Science ends three studies in multiple sclerosis, other immune conditions

Published

on

The trials, which were testing the tyrosine kinase inhibitor masitinib, had previously been paused. AB Science’s decision not to resume them was a matter of prioritization, not safety, the biotech said.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version